

1 **Rising prevalence of *Plasmodium falciparum* artemisinin resistance mutations in**
2 **Ethiopia**

3 Bokretzion G. Brhane^{1,2*}, Abebe A. Fola^{3,4*}, Helen Nigussie², Alec Leonetti³, Moges
4 Kassa¹, Henok Hailgiorgis¹, Yonas Wuletaw¹, Adugna Abera¹, Hussein Mohammed¹,
5 Heven Sime¹, Abeba G/Tsadik¹, Gudissa Assefa⁹, Hiwot Solomon⁹, Geremew Tasew¹,
6 Getachew Tollera¹, Mesay Hailu¹, Jonathan J. Juliano^{5,6,7,8}, Ashenafi Assefa^{1,4},
7 Jonathan B. Parr^{5,6,7#} and Jeffrey A. Bailey^{3,4#}

8
9 1 Ethiopian Public Health Institute, Addis Ababa, Ethiopia
10 2 Department of Microbial, Cellular, and Molecular Biology, Addis Ababa University,
11 Addis Ababa, Ethiopia
12 3 Department of Pathology and Laboratory Medicine, Brown University, Providence, RI,
13 USA
14 4 Center for Computational Molecular Biology, Brown University, Providence, RI, USA
15 5 Institute for Global Health and Infectious Diseases and Division of Infectious
16 Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel
17 Hill, NC, USA
18 6 Division of Infectious Diseases, School of Medicine, University of North Carolina at
19 Chapel Hill, Chapel Hill, NC, USA
20 7 Curriculum in Genetics and Molecular Biology, School of Medicine, University of North
21 Carolina at Chapel Hill, Chapel Hill, NC, USA
22 8 Department of Epidemiology, Gillings School of Global Public Health, University of
23 North Carolina at Chapel Hill, Chapel Hill, NC, USA
24 9 Ministry of Health, Addis Ababa, Ethiopia

25
26
27

28

29

30 Abstract

31 Ethiopia is striving to eliminate local malaria transmission by 2030, despite a recent
32 resurgence of malaria cases due to multiple factors. A significant contributor to this
33 resurgence could be drug resistance, particularly the emergence of partial resistance to
34 artemisinin (ArtR) in Ethiopia and other regions of Eastern Africa. This situation
35 highlights the necessity for genomic surveillance to monitor relevant drug resistance
36 markers. This study reports sentinel site-based genomic surveillance results for *P.*
37 *falciparum* antimalarial drug resistance mutations. From 2019 to 2022, dried blood spots
38 (DBS) were collected from febrile outpatients ≥ 1 year of age with microscopically
39 confirmed falciparum malaria at 12 sentinel sites across 5 regions. Molecular inversion
40 probe (MIP) sequencing targeted mutations associated with artemisinin and partner
41 drug resistance, including *k13*, *mdr1*, *crt*, *dhfr*, and *dhps* genes, along with genome-
42 wide markers to assess the complexity of infection (COI) and parasite relatedness. A
43 total of 1,199 falciparum-positive patients were assessed, with a median age of 20
44 years (IQR: 14-30) and including 463 (38.6%) females. The WHO-validated K13 R622I
45 mutation had a high but regionally variable prevalence (15.7%, range 0-58.8%). The
46 validated K13 A675V mutation was detected for the first time in Ethiopia in the
47 Gambella Region (4.5%), as well as P441L and P574L mutations were detected at low
48 frequencies in Southern and Oromia Regions, respectively. Several partner drug
49 resistance markers were identified, with mutations in MDR1(184F), DHPS, DHFR, and
50 CRT nearly fixed across the country. Most samples (87.2%) were monogenic infections
51 (COI=1) and showed high genetic relatedness, particularly within the health facilities.
52 Principal component analysis revealed regional clustering of parasites, particularly in
53 Gambella. The prevalence of K13 R622I across the country and the presence of
54 multiple additional ArtR markers emphasizes the urgent need for rigorous monitoring of
55 artemisinin combination therapy (ACT) efficacy to detect partner drug resistance and
56 ACT failure early and its impact on malaria resurgence in Ethiopia.

57

58

59

60 Keywords

61 Malaria, *Plasmodium falciparum*, drug resistance, genomics, sentinel site, Ethiopia

62

63

64

65

66

67

68

69

70

71

72 Background

73 Malaria remains a significant public health challenge in Africa, accounting for
74 approximately 95% of malaria cases and 96% of malaria deaths, predominantly
75 affecting children under five and pregnant women¹. Despite notable progress through
76 the use of artemisinin-based combination therapies (ACTs), vector control measures,
77 and vaccines like RTS,S, the path to eliminating malaria faces formidable obstacles^{2,3}.
78 These challenges include the emergence of drug- and diagnostic-resistant parasites⁴⁻⁷,
79 insecticide-resistant mosquitoes⁸, new invasive mosquito species⁹, inadequate
80 healthcare infrastructure, and funding gaps¹⁰. Resistance to artemisinin poses a
81 particular threat to the efficacy of ACTs in Africa^{11,12} and progress towards malaria
82 elimination, highlighting the need for new strategies to define and mitigate the impact of
83 antimalarial resistance.

84
85 Artemisinin partial resistance (ArtR) was first reported in western Cambodia in
86 Southeast Asia in 2006-2007^{13,14} and has since spread or emerged independently in
87 other countries in the Greater Mekong Subregion¹⁵, South America¹⁶, and recently in
88 Eastern Africa¹⁷⁻¹⁹ and the Horn of Africa^{5,20}. The rise of ArtR WHO-validated markers
89 have been confirmed in Ethiopia⁵, Eritrea²⁰, Rwanda¹⁷, Uganda²¹, Tanzania⁶, and
90 Democratic Republic of the Congo (DRC)²². ArtR likely accelerates the emergence of
91 resistance to partner drugs²³, and once combined with partner drug resistance lead to
92 significant clinical failure in Southeast Asia. Frank partner drug resistance mutations
93 have not been found in Africa. Amino acid polymorphisms in the multidrug resistance
94 protein 1 (MDR1) and chloroquine resistance transporter (CRT) are well established
95 and partially effect susceptibility diametrically to both amodiaquine and possibly
96 lumefantrine²⁴, which are the most common partner drugs used in ACTs in Ethiopia and
97 most of Africa. This decreased susceptibility likely further undermines ACTs increasing
98 the potential for emergence of other mutations^{4,6}.

99
100 Despite Ethiopia's gains in malaria control over the past two decades, the country faces
101 increasing malaria cases in various regions, in the setting multiple challenges: First, the
102 K13 622I mutation, a validated marker of partial artemisinin resistance, has been found
103 at significant frequencies, particularly in the north of the country⁵. Second, the rise of *P.*
104 *falciparum* strains with *hrp2* and *hrp3* gene deletions complicates the reliability of rapid
105 diagnostic tests (RDTs), contributing to diagnostic failures and potentially increasing
106 transmission^{5,7}. Third, invasive urban-adapted mosquito species^{9,25}, and increasing
107 insecticide resistance threaten malaria control efforts²⁶. Fourth, environmental and man-
108 made factors such as climate change²⁷, conflict, and population movement may have
109 facilitated the spread of malaria, contributing to the recent resurgence. Gaps in
110 surveillance systems hinder effective tracking of disease patterns and resistance trends
111 and understanding the role of these challenges in malaria resurgence. Dissecting and

112 addressing these challenges requires enhanced surveillance, robust diagnostic tools,
113 and innovative strategies to track and mitigate the spread of drug-resistant strains to
114 achieve elimination goals²⁸. Genomic surveillance of molecular markers of resistance
115 and understanding the genomic diversity of the parasite will be critical²⁹. Such
116 surveillance helps identify resistance hotspots and informs targeted interventions such
117 as deployment of sequential or triple ACT regimens, contributing to more effective
118 malaria control and elimination strategies^{30,31}.

119

120 Integrating genomic data with routine surveillance systems for timely tracking of
121 emerging and spreading resistance is crucial^{32,33}. To this end, the Ethiopian Public
122 Health Institute (EPHI), in collaboration with the national malaria control and elimination
123 program, established a network of sentinel sites representative of the diverse malaria
124 transmission ecologies across the country. These sites collect and analyze data on
125 malaria transmission dynamics, treatment efficacy, and resistance patterns, providing
126 opportunities for evidence-based decision-making in near real-time. These sentinel sites
127 are integral to Ethiopia's broader malaria control and elimination strategy, which aims to
128 reduce the disease's burden through early detection, targeted treatment, and prevention
129 efforts. This study reports an in-depth analysis of the emergence and spread of drug
130 resistance mutations and parasite relatedness using molecular inversion probe (MIP)
131 sequencing of samples collected from 12 sentinel sites across the country.

132

133 **Results**


134 **Study population**

135 After filtering, 855 of 1,199 samples were included in the analysis sample set (**Figure**
136 **S1**). Samples came from participants enrolled at all 12 sentinel site health facilities
137 (**Figure 1A**) across five regions (Amhara = 270, Gambella = 131, Oromia = 193, SNNP
138 = 221, Somali = 40) (**Figure 1B**). The median parasite density of sequenced samples
139 was 2,000 parasites/ μ L (range 48 to 61,000 parasites/ μ L) by microscopy, with better
140 sequencing coverage in samples with higher parasitemia (**Figure S1**). Most samples (n
141 = 767) were collected in 2022 and 79.2% (n = 607) were successfully genotyped, 393
142 collected in 2019 and 56.9% (n=224) successfully genotyped followed 39 collected in
143 2023 and 61.5% (n = 24) successfully genotyped. Details of samples successfully
144 sequenced per each MIP panel summarized in **Table S1** and **Table S2**.

145

146

147



148
149 **Figure 1. Study sites and sequenced samples. A) Study sites and B) distribution of**
150 **samples sequenced per health facility and region. Colors indicate individual health**
151 **facilities.**


152 Prevalence and distribution of ArtR mutations

153 We first assessed the prevalence of WHO-validated and candidate K13 ArtR mutations
154 revealing four WHO validated K13 mutations (**Figure 2A**). K13 R622I was the most
155 prevalent (15.7% [95% CI 13.2-18.2%]). Its geospatial distribution was heterogeneous
156 (prevalence range: 0 to 58.8%) at health facility level (**Figure S2**), with highest regional
157 prevalence in the north (46.9% [95% CI 40.7-53.2%]) in the Amhara region) where it was
158 first reported at 2.4% in one facility in 2014³⁴. K13 R622I was also prevalent in Erer
159 (12.9%), a Somali region Eastern part of the country, and additionally observed in low
160 frequency from health facilities from Gambela and Oromia regions but not reported from
161 health facilities from SNNP (Southern Nations, Nationalities and Peoples) region.

162
163 Of concern, we found three additional WHO-validated K13 mutations not previously
164 observed in the Horn of Africa or Ethiopia in the southern half of the country where 622I
165 is not as prevalent. We found 6 samples with A675V (Gambella Region), 4 samples with
166 P441L (3 from Southern Region including 2 from Dilla and 1 from Secha health centers,
167 and 1 from Oromia Region in the Metehara health center) and 5 samples with P574L
168 (Oromia Region in the Batu health center) (**Table S3**). We also identified an additional
169 14 non-synonymous mutations within and outside the K13 propeller domain with
170 variable frequencies (**Figure S3**). Other K13 mutations not associated with ArtR were
171 found, including K189T at 32% (CI, 27.1- 38.3) prevalence across sites.

172 Genetic relatedness of k13 mutant parasites

173 To further elucidate the spatial spread of mutant parasites, we conducted IBD
174 relatedness analysis and found that there was a higher average IBD sharing estimate
175 for K13 R622I mutant isolates compared to K13 wild-type isolates (**Figure 2B**). This
176 was also true for parasites carrying P574L mutations (**Figure S4B**), however, parasites
177 carrying A675V or P441L did not show significant relatedness and were in fact less
178 related compared to wildtype (**Figure S4A, C**). We then conducted relatedness network
179 analysis, using an IBD cut of ≥ 0.99 to detect evidence of clonal transmission, finding
180 clustering mutant parasites clustered into pairs and networks (**Figure 2C**) separate from
181 wildtype.
182




183
184 **Figure 2. WHO-validated K13 mutation prevalences and relatedness of 622I**
185 **mutant vs wildtype parasites.** **A)** Spatial distribution of WHO-validated K13 mutations
186 by health facility (pie charts). Colors indicate which mutation, and pie chart size is
187 proportional to sample size per study site. **B)** Pairwise IBD sharing within *kelch13* R622I
188 mutant versus wild parasites, showing *** significant differences ($P < 0.001$, two-
189 tailed, Mann-Whitney *U*-test). Boxes indicate the interquartile range, the line indicates
190 the median, the whiskers show the 95% confidence intervals and dots show outlier
191 values. *P* value determined using Mann-Whitney test is shown. **C)** Network analysis
192 showing highly related parasite pairs ($IBD \geq 0.99$). Each node identifies a unique isolate,
193 and an edge is drawn between two isolates if they meet the IBD threshold. Isolates that
194 do not have a IBD pairwise connection above threshold are not shown. Color codes
195 correspond to K13 R622I mutant (pink) and wild parasites (blue green).

196
197
198
199

Prevalence of mutations associated resistance to partner drugs

200 Mutations in the *P. falciparum* multidrug-resistance gene 1 (MDR1), particularly isolates
201 that carry the N86 (wild), 184F (mutant), and D1246 (wild) haplotype have been
202 associated with modest decreased susceptibility to lumefantrine (the first line partner
203 drug in Ethiopia, co-formulated as artemether-lumefantrine). Our analysis revealed that
204 99.1% ([95% CI 98.4-99.6%]) sequenced samples carried N86 (wild), followed by 98.1%
205 ([95% CI 97.2-98.9%]) samples of D1246 (wild), and 94.8% ([95% CI 93.4-96.3%])
206 carrying 184F (mutant) (**Figure 3A**). The overall high prevalence resulted in less spatial
207 variation at district or health center level (data not shown). Nearly all parasites with the
208 ArtR K13 R622I (**Figure 3A**) and A567V (**Figure 3B**) mutations also carry the MDR1
209 NFD haplotype associated with lumefantrine resistance. The co-occurrence of ArtR and
210 partner drug resistance mutations raises concern about the effectiveness of ACTs in
211 Ethiopia.



212

213 **Figure 3. Co-occurrence of ArtR and lumefantrine-resistance markers in Ethiopia.**
214 Number of parasites with **A)** K13 622I and MDR1 N86 (wild), 184F (mutant) and D1246
215 (wild) and with **B)** K13 675V and MDR1 N86 (wild), 184F (mutant) and D1246 (wild).
216 Only samples with calls across all loci are shown. For polygenomic infections, the
217 dominant haplotype ($\geq 51\%$ allele frequency) is shown.

218

219 We also observed a high prevalence of mutations associated with resistance to
220 sulfadoxine-pyrimethamine (SP) and chloroquine. SP was discontinued in 2004 and is
221 not used for intermittent preventive treatment for pregnant women (IPTp) as in other
222 African countries. Nonetheless, SP resistance mutations persist at high prevalence. In
223 DHFR, 98.9% ([95% CI 98.6-99.4%]) parasites had the S108N mutation, 98.5% ([95%

224 CI 97.8-99.3%]) N51I, and 65% ([95% CI 61.9-68.1%]) C59R (**Figure S5A**) mutations
225 associated with pyrimethamine resistance. Overall, 469 (61.6%) samples carry all three
226 mutations (DHFR IRN, triple mutant) with low spatial heterogeneity at regional level
227 across the country. None of the genotyped samples carried DHFR 164L, a mutation
228 associated with higher levels of SP resistance. Analysis of markers associated with
229 sulfadoxine resistance revealed that all 907 (100%) isolates carried DHPS A437G and
230 83.1% ([95% CI 80.6-85.4%]) K540E, with 711 (78.8%) carrying both of these mutations
231 (DHPS GE, double mutant) (**Figure S5A**). The DHPS A581G mutation, shown to
232 increase SP resistance, when co-occurring with the above mutations occurred at low
233 frequency, 3.4% ([95% CI 2.6-5.4%]) (**Figure S5A**).

234


235 Chloroquine is widely used in Ethiopia for treatment of *Plasmodium vivax* infection.
236 Mutations in the *P. falciparum* chloroquine (CQ) resistance transporter (CRT) were
237 common; 896 (82.4%) parasites had the chloroquine-resistance marker 76T. All regions
238 had high prevalence with the exception of Gambela in the southwest 7.6% ([95% CI
239 5.2-8.4%]) (**Figure S5B**). Additional mutations in CRT are provided in **Table S3**.

240

241 **Complexity of infection and parasite population structure**

242 The majority of sequenced samples were monogenomic 745 (87.1%) (**Figure S6A**),
243 consistent with previous reports^{5,35}, with some level variation in complexity of infection
244 at the regional level (**Figure 4A**). The maximum COI detected was 4 (from Gambella
245 Region) likely reflecting relatively low transmission in the study areas. Principal
246 components (PC) 1 and 2 revealed distinct clustering of parasites from Gambella,
247 supporting regional differentiation of the *P. falciparum* population within Ethiopia, but not
248 by K13 622I status (**Figure 4B, Figure S7**).

249



250

251 **Figure 4.** Complexity of infection and population structure of *P. falciparum* in Ethiopia.

252 **A)** Complexity of infections for *P. falciparum* at a regional level. Colors indicate regions

253 and black dots inside violin plots indicate median COI. **B)** PCA plot of *P. falciparum*
254 population at regional level. Colors indicate geography of sample origins and shapes
255 indicate mutation K13 R622I status. Each diamond or dot indicates individual parasites.
256 Percentage of variance explained by each PCA presented in each plot.
257

258 **Spatial patterns of parasite relatedness and connectivity**

259 We conducted IBD analysis of monogenomic infections to further elucidate the
260 connectivity of the parasite population across different regions. Overall, we observed a
261 tailed distribution of highly related parasite pairs (**Figure 5A**) with some level of spatial
262 heterogeneity of proportion of pairs IBD for parasite population at each health center
263 (**Figure 5B**). The lowest average IBD sharing observed at Abol health center, Gambella
264 Region. We then conducted relatedness networks analysis to assess where haplotypes
265 sharing IBD above the specified threshold cluster geographic region or sample origin
266 and found clear clustering of highly related parasite pairs ($IBD \geq 0.90$) within health
267 centers suggesting inbreeding and clonal transmission at local scale (**Figure 5C**).
268 However, occasional sharing of nearly clonal parasites was seen between clinics,
269 suggesting long range parasite sharing. To identify if transmission of highly related
270 parasite pairs ($IBD \geq 0.90$) were occurring between clinics in a within a region and
271 between different regions, we visualized a relatedness network on top of the Ethiopia
272 map and found that majority of the highly related pairs were distributed within regions or
273 nearby regions than distant regions. Connections between Gambella and other regions
274 were rare (**Figure 5D**).

275

276

277

278

279


280

281

282

283

284



285

286

287 **Figure 5. *P. falciparum* parasite relatedness and connectivity across Ethiopia. A)**

288 Pairwise IBD sharing across 12 health facilities. The plot shows the probability that any

289 two isolates are identical by descent, where the x axis indicates IBD values and the y

290 axis indicates the frequency (%) of isolates sharing IBD. The inset highlights highly

291 related parasite pairs with a heavy tail in the distribution and some highly related pairs

292 of samples having $IBD \geq 0.90$. **B)** Pairwise IBD sharing within a health facility. Boxes

293 indicate the interquartile range, the line indicates the median, the whiskers show the

294 95% confidence intervals and dots show outlier values. **C)** Relatedness network of

295 highly related parasite pairs ($IBD \geq 0.90$) at study site. Each dot indicates a sample and

296 colors correspond to health facilities across five regions in Ethiopia. Each node

297 identifies a unique isolate and an edge is drawn between two isolates if they share their

298 genome above $IBD \geq 0.90$. Isolates that do not share $IBD \geq 0.90$ of their genomes with

299 any other isolates are not shown. **D)** Spatial distribution of highly related parasite pairs
300 with $IBD \geq 0.90$. Color of circles or connecting lines represents the level of IBD sharing
301 within and between sites, respectively. The within site shading is based upon the most
302 related pair of parasites at the site.

303 **Discussion**

304 Findings from our genomic analysis of parasites collected across sentinel sites
305 predominantly in 2022 suggest a critical threat of ArtR to ACT effectiveness in Ethiopia.
306 We identified increased prevalence and evidence of spread of the previously identified
307 WHO-validated ArtR K13 622I, with marked increases compared to previous reports.
308 Here we see a prevalence of 622I up to 53.7% in Andansa Health Centre within the
309 Amhara region, as compared to 10% in 2018⁵ and 2.4% in 2014³⁴. Parasites carrying
310 622I are more closely related and clustered at health facility/district level compared to
311 wildtype parasites.

312 These findings are consistent with our previous report of clonal transmission in three
313 regions of Ethiopia⁵. The highly-related, clonal nature of K13 622I mutant parasites
314 compared to wildtype parasites in this study is consistent with inbreeding and increasing
315 frequency within populations, especially in low transmission areas^{36,37}. Our findings
316 highlight the value of establishing genomic surveillance at malaria sentinel sites,
317 particularly how it can play a crucial role in tracking the emergence and spread of drug-
318 resistant strains by providing continuous and localized monitoring of malaria parasite
319 populations. It also provides deeper insight into the genetic population structure of
320 parasites circulating at these sites. Researchers in collaboration with the malaria control
321 program can detect early signals of resistance development, understand its
322 geographical spread, and assess the effectiveness of current treatments^{38,39}.

323 In addition to K13 622I, three WHO-validated K13 mutations (A675V from Gambella
324 Region; P441L from South and Oromia Regions, and P574L from Oromia Region) are
325 reported for the first time in Ethiopia. These K13 mutations are becoming more common
326 in East Africa^{18,40-42}. The K13 441L mutation found in three health centers from different
327 geographic areas with variable malaria transmission and a recent increase in malaria
328 cases. The validated K13 P574L mutation was present in 5 samples from only one site,
329 Batu health center in the Oromia region. K13 P574L mutations have each been shown
330 to have multiple independent origins throughout SE Asia⁴³ and have been reported in
331 Africa⁴⁴.

332 The K13 675V mutation was only found in one health center from Gambella Region of
333 western Ethiopia neighboring South Sudan. This mutation was reported in isolates
334 collected in Uganda beginning in 2016. It has proven to enhance parasite survival *in*

335 *vitro* and has been associated with resistance *in vitro*^{42,45}. Importation of the 675V
336 mutation seems probable given the IBD analysis showed lower relatedness and 4/6 of
337 the participants with the mutation reported travel. However, we cannot confirm whether
338 the haplotype carrying this mutation are imported or locally emerged due lack of publicly
339 available WGS data with K13 675V mutations from East Africa. Potentially supporting
340 the impact of travel and importation on parasites in Ethiopia, the parasite population
341 from Gambella did not cluster with other parasite populations in the country. This
342 differentiation could be for multiple reasons, such as different travel patterns in the
343 country, potentially supported by the low number of long-distance connections with
344 other clinics (**Figure 5D**). However, Gambella also shares a border with South Sudan
345 and receives a large number of refugees from across the border. Recent studies of
346 South Sudanese refugees entering and arriving at the Ugandan Adjumani refugee camp
347 show 15.4% prevalence of 675V⁴⁶. Combined, this suggests that 675V may be
348 spreading rapidly across South Sudan thereby entering Ethiopia.

349 Different studies propose that high efficacy of partner drugs, high prevalence of
350 polygenomic infections, and high parasite genetic diversity impede the spread of ACT
351 resistance in Africa^{21,47,16}. However, in this study we found a high prevalence of
352 mutations associated with lumefantrine resistance⁴⁸. The majority of genotyped samples
353 carried the MDR1 NFD haplotype^{49,50}, but three parasites with WHO-validated ArtR
354 markers in our study carry MDR1 NFD haplotypes that could lead to ACT failure.
355 Recent study showed that there is increasing prevalence of MDR1 NFD haplotypes in
356 recent years in East Africa⁵¹. Moreover, the rollout of ACTs has led to an increase in the
357 MDR1 NFD haplotypes across several African studies, suggesting parasite populations
358 in Africa are under significant ACT selective pressure⁴⁹. With reports of decreased ACT
359 efficacy and treatment failure in Africa⁵²⁻⁵⁴, the presence of partner drug mutations and
360 high prevalence of monogenomic infections suggests the conditions are ripe for ACT
361 failure in Ethiopia. Thus, close monitoring of ACT efficacy and preparation for
362 deployment of alternative treatment strategies (e.g. multiple sequential therapies,
363 sequential ACT or triple ACT) are needed.

364 This study does have limitations. First it does not address whether the mutations are
365 directly emerging locally or are imported. This will be possible as more genomic
366 information is produced from other areas of Africa and whole genome sequencing of
367 these isolates is done allowing for accurate tracking of K13 haplotypes. Second, it did
368 not address the impact of these mutations on clinical resistance as the *in vitro* efficacy
369 was not evaluated. Third, 12 sentinel sites do not represent the entirety of malaria
370 epidemiology or parasite populations circulating in Ethiopia. Nonetheless, sampling
371 across most regions of the country provides valuable, generalizable information for the
372 malaria control program. Despite these limitations, these data provide important findings
373 about how ArtR is spreading in the Horn of Africa which is critical information for malaria

374 control programs. Lastly, our data suggests importation and population movement may
375 play a role in the genetic patterns seen, but we do not have details on locations and
376 duration of travel to test this.

377 In conclusion, this study highlights critical challenges for malaria control including: 1) the
378 continued emergence and spread of the validated 622I mutation, 2) the detection of new
379 validated ArtR mutations in the Horn of Africa, and 3) the high rate of the co-occurrence
380 of ArtR with the MDR1 NFD haplotype associated with reduced sensitivity to
381 lumefantrine, the key partner drug in the region. It also raises additional questions about
382 the impact of importation and travel on the spread of antimalarial resistance, questions
383 that will be answered as more genomic data from Africa becomes available. We also
384 demonstrate that sentinel surveillance systems can leverage genomics to provide
385 critical information to control programs and potentially can help target where *in vivo*
386 studies should be focused to determine the clinical impacts of antimalarial resistance
387 polymorphisms, as was done for validated ArtR in Tanzania due to the 561H
388 mutation^{11,41}. All of East Africa and the Horn of Africa are going to face significant
389 challenges in the years to come due to emerging antimalarial resistance, and malaria
390 molecular surveillance will play a key role in fighting this emerging threat^{4,6,55}.

391

392 **Methods**

393 **Study sites and sample collection**

394 EPHI maintains 25 malaria sentinel sites, representing the variable eco-epidemiological
395 zones across the country. A series of cross-sectional studies were conducted in 12 of
396 these sites between 2019 and 2022 to assess the emergence and prevalence of
397 antimalarial drug resistance markers. The study sentinel sites included at least one area
398 where large scale industry and irrigation, typically for sugar, is occurring and one
399 location in a border area (**Figure 1A**). From September to November of each year,
400 patients attending the outpatient department with signs and symptoms of malaria were
401 screened by microscopy. Microscopy occurred in the field and was reviewed by a
402 second expert microscopist at EPHI. In cases of discordance, a third reader was used,
403 blinded to previous reads. Inclusion criteria included *P. falciparum* positive by
404 microscopy. Patients less than 1 year or with severe malaria were excluded. Following
405 consent, a brief questionnaire was performed (including patient age, sex, malaria sign
406 and symptoms, travel history and demography), and dried blood spot (DBS) samples
407 were blotted onto Whatman 3 filter paper, air-dried, placed individually in a plastic bag
408 containing silica gel desiccant. These were stored at room temperature prior to transport
409 to EPHI, and stored at -20 °C until used.

410

411 **DNA extraction and MIP sequencing**

412

413 DNA was extracted from DBS (one full DBS spot, typically involving 2 or 3 6mm
414 punches) using Chelex-Tween as previously described⁵⁶.

415

416 Five microliters of extracted DNA were used for each of the MIP captures using two
417 panels: one covering key *P. falciparum* drug resistance genes and mutations, including
418 *k13*, *mdr1*, *crt*, *dhfr*, and *dhps* genes, and a newly designed panel of 305 MIPs targeting
419 common SNPs (>5%) SNPs (**Table S4**) (Niare *et al.* in preparation). MIP capture and
420 library preparation were performed as previously described^{5,57}. Sequencing was
421 conducted using an Illumina NextSeq 550 instrument (150 bp paired-end reads) at
422 Brown University (RI, USA). For samples with newly detected K13 441L, 574L and
423 675V, mutations in Ethiopia, an additional MIP capture was done using the same MIP
424 panel and resequenced to a high depth to confirm the mutations. Controls for each MIP
425 capture and sequencing included genomic DNA from serial dilution of lab strain 3D7 as
426 well as no template and no probe controls.

427

428 **Variant calling and filtering**

429 The sequencing reads generated for each MIP panel were demultiplexed separately
430 using MIPtools software (<https://github.com/bailey-lab/MIPTools>) and further processed
431 using MIP Wrangler software (<https://github.com/bailey-lab/MIPWrangler>), in which
432 sequence reads sharing the same Unique Molecular Identifiers (UMIs) were collapsed
433 to generate a single consensus. Each dataset was analyzed by mapping sequence
434 reads to the *P. falciparum* 3D7 reference genome using Burrows-Wheeler Aligner
435 (BWA)⁵⁸. Then variant calling was performed using freebayes software⁵⁹. To reduce
436 false positives due to PCR and alignment errors, the alternative allele needed to be
437 supported by more than one UMI within a sample, and the allele must have been
438 represented by at least 10 UMIs across the entire population. For genome wide SNPs,
439 only biallelic variant SNP positions were retained for downstream analysis. Low quality
440 SNPs (mapping quality < 30), were removed from the analysis using vcftools⁶⁰;
441 additionally, individual variant calls within each sample were set to missing if the site
442 was not supported by at least five UMIs. After these steps, SNPs with more than 50%
443 missing data across samples, and subsequently samples with more than 50% of SNPs
444 missing, were removed from all downstream analyses⁵.

445 **Drug resistance prevalence estimation**

446 For drug resistance analysis, variants were annotated using the *Pf 3D7* v3 reference
447 genome and gene features. Variants with a unique UMI count of 3 or greater used to
448 estimate prevalence key and known drug resistance mutations associated with different
449 antimalarial resistance using the *miplicorn* package R 4.2.1 software
450 (<https://github.com/bailey-lab/miplicorn>) and custom R script. With the exception of the
451 DHPS 437 mutation (which is mutant in the reference genome), drug resistance
452 prevalence was determined considering both heterozygous or homozygous variants as
453 mutant alleles, while homozygous reference alleles considered as wild-type, and
454 missing loci not included for prevalence calculation ($p=x/n*100$), where p = prevalence,
455 x = number of mutant alleles, n = number of successfully genotyped loci. n is different
456 for each locus as each locus had independent success rates for genotyping. Prevalence
457 and frequency bar plots were generated using the *ggplot2* package and spatial
458 visualization of prevalence on maps of study areas were created using the *sf* package in
459 R 4.2.1 software. Analysis of haplotypes included only samples where complete
460 genotypes across all involved variant sites were available and was plotted and
461 visualized using the *UpSet* package in R 4.2.1 software. Finally, the prevalence of each
462 drug resistance marker was calculated at the health facility level.

463 **Analysis of complexity of infectious and parasite population structure**

464 The complexity of infection (COI) is the number of distinct parasite clones infecting a
465 single host. To estimate the number of clones per sample, the VCF file containing SNP
466 data was converted to THE REAL McCOIL categorical method format: heterozygous
467 call as 0.5, homozygous reference allele as 0, homozygous alternative allele as 1 and
468 no call as -1 and used as an input file for analysis of COI using THE REAL McCOIL R
469 package. To assess whether parasite populations within Ethiopia clustered per their
470 geographic origin, or by mutation status, we conducted principal component analysis
471 (PCA) using *SNPRelate* function in R 4.2.1 software and the result was visualized
472 *ggplot2*.

473 **Analysis of parasite relatedness using Identity-by-descent (IBD)**

474 We used identity-by-descent (IBD) to measure relatedness between parasites and
475 identify regions of the genome shared with recent common ancestry using the
476 *inbreeding_mle* function in MIPAnalyser software (v.1.0.1) (<https://github.com/mrc-ide/MIPAnalyser>)
477 in R 4.2.1 software as previously described⁶¹. In brief, both
478 monogenomic and polygenomic infections (major alleles used for heterozygous
479 positions) were included in the IBD analysis. *Inbreeding_mle* uses a Markov chain
480 Monte Carlo to detect genomic regions that are identical by descent (IBD) and aids

481 simultaneous detection of parasite population clustering. Networks of highly-related
482 parasites per k13 mutation status or geographic origin (health facilities) created using
483 the *igraph* package in R 4.2.1 software. We then assessed IBD sharing at the regional
484 and local (health facility level) scales in order to assess spatial distribution of the
485 parasite population.

486 487 **Data availability**

488 All data produced in the present study are available upon reasonable request to the
489 authors.

490
491 **Funding:** This work was funded by the World Bank through the Africa CDC, with partial
492 support from the National Institute for Allergy and Infectious Diseases (R01AI177791 to
493 JBP, K24AI134990 to JJJ, and R01AI139520 to JAB).

494 495 **Ethics**

496 Before the commencement of the study, scientific and ethical approval was obtained
497 from the Ethiopian Public Health Institute's Institutional Review Board (EPHI-IRB),
498 protocol number EPHI-IRB-398-2021. In addition, respective permission and supporting
499 letters were obtained from the health facilities administration. All the necessary
500 precautionary and ethical methods were considered during the implementation of the
501 study for the patients and investigators. All screening forms and case record forms are
502 kept in a secured location, with access limited to authorized staff members. Unique
503 numerical identifiers were used for the computer-based data entry and blood samples.
504 Genotyping work conducted at Brown University was considered non-human subjects
505 research. Only aggregated clinical data and de-identified samples used for reporting
506 individual level genotypes for publication.

507 **Author contributions**

508 BGB, AA, AAF, JBP, JJJ and JAB conceived the study. BGB led patient recruitment and
509 sample collection with contributions from HN, MK, HH, YW, GT, AA, MH, HS, AG, GA,
510 HS, GT and AA. BGB, AL and AAF performed laboratory work. BGB and AAF led
511 genetic data analysis and wrote the first draft of the manuscript. AA, JBP, JJJ and JAB
512 supported genetic data analysis and interpretations of results. All authors contributed to
513 the writing of the manuscript and approved the final version before submission.

514 **Acknowledgments**

515 The authors used an artificial intelligence language model for English language editing
516 during the writing process. However, the manuscript is original to the authors, who take
517 responsibility for its content.

518

519

520 **Competing interests:** JBP reports research support from Gilead Sciences, non-
521 financial support from Abbott Laboratories, and consulting for Zymeron Corporation, all
522 outside the scope of the current manuscript.

523 References

- 524 1. World Health Organization. *World Malaria Report 2023*. (World Health
525 Organization, 2023).
- 526 2. Bhatt, S. *et al.* The effect of malaria control on *Plasmodium falciparum* in Africa
527 between 2000 and 2015. *Nature* **526**, 207–211 (2015).
- 528 3. Beeson, J. G. *et al.* The RTS,S malaria vaccine: Current impact and foundation for
529 the future. *Sci. Transl. Med.* **14**, eabo6646 (2022).
- 530 4. Rosenthal, P. J. *et al.* The emergence of artemisinin partial resistance in Africa:
531 how do we respond? *Lancet Infect. Dis.* (2024) doi:10.1016/S1473-3099(24)00141-
532 5.
- 533 5. Fola, A. A. *et al.* *Plasmodium falciparum* resistant to artemisinin and diagnostics
534 have emerged in Ethiopia. *Nat Microbiol* **8**, 1911–1919 (2023).
- 535 6. Ishengoma, D. S. *et al.* Urgent action is needed to confront artemisinin partial
536 resistance in African malaria parasites. *Nat. Med.* (2024) doi:10.1038/d41591-024-
537 00028-y.
- 538 7. Feleke, S. M. *et al.* *Plasmodium falciparum* is evolving to escape malaria rapid
539 diagnostic tests in Ethiopia. *Nat Microbiol* **6**, 1289–1299 (2021).
- 540 8. Zinszer, K. & Talisuna, A. O. Fighting insecticide resistance in malaria control.
541 *Lancet Infect. Dis.* **23**, 138–139 (2023).
- 542 9. Emiru, T. *et al.* Evidence for a role of *Anopheles stephensi* in the spread of drug-
543 and diagnosis-resistant malaria in Africa. *Nat. Med.* **29**, 3203–3211 (2023).
- 544 10. Nkumama, I. N., O'Meara, W. P. & Osier, F. H. A. Changes in Malaria
545 Epidemiology in Africa and New Challenges for Elimination. *Trends Parasitol.* **33**,
546 128–140 (2017).
- 547 11. Ishengoma, D. S. *et al.* Evidence of artemisinin partial resistance in northwestern
548 Tanzania: clinical and molecular markers of resistance. *Lancet Infect. Dis.* (2024)
549 doi:10.1016/S1473-3099(24)00362-1.
- 550 12. Tumwebaze, P. *et al.* Changing Antimalarial Drug Resistance Patterns Identified by
551 Surveillance at Three Sites in Uganda. *J. Infect. Dis.* **215**, 631–635 (2017).
- 552 13. Dondorp, A. M. *et al.* Artemisinin resistance in *Plasmodium falciparum* malaria. *N.*
553 *Engl. J. Med.* **361**, 455–467 (2009).
- 554 14. Noedl Harald *et al.* Evidence of Artemisinin-Resistant Malaria in Western
555 Cambodia. *N. Engl. J. Med.* **359**, 2619–2620.
- 556 15. Tun, K. M. *et al.* Spread of artemisinin-resistant *Plasmodium falciparum* in
557 Myanmar: a cross-sectional survey of the K13 molecular marker. *Lancet Infect. Dis.*
558 **15**, 415–421 (2015).
- 559 16. Ashley Elizabeth A. *et al.* Spread of Artemisinin Resistance in *Plasmodium*
560 *falciparum* Malaria. *N. Engl. J. Med.* **371**, 411–423.

- 561 17. Uwimana, A. *et al.* Author Correction: Emergence and clonal expansion of in vitro
562 artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in
563 Rwanda. *Nat. Med.* **27**, 1113–1115 (2021).
- 564 18. Young, N. W. *et al.* High frequency of artemisinin partial resistance mutations in the
565 great lake region revealed through rapid pooled deep sequencing. *medRxiv* (2024)
566 doi:10.1101/2024.04.29.24306442.
- 567 19. Juliano, J. J. *et al.* Prevalence of mutations associated with artemisinin partial
568 resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in
569 2021: a cross-sectional survey. *Lancet Microbe* 100920 (2024).
- 570 20. Mihreteab, S. *et al.* Increasing Prevalence of Artemisinin-Resistant HRP2-Negative
571 Malaria in Eritrea. *N. Engl. J. Med.* **389**, 1191–1202 (2023).
- 572 21. Balikagala, B. *et al.* Evidence of Artemisinin-Resistant Malaria in Africa. *N. Engl. J.*
573 *Med.* **385**, 1163–1171 (2021).
- 574 22. van Loon, W. *et al.* Detection of Artemisinin Resistance Marker Kelch-13 469Y in
575 *Plasmodium falciparum*, South Kivu, Democratic Republic of the Congo, 2022. *Am.*
576 *J. Trop. Med. Hyg.* **110**, 653–655 (2024).
- 577 23. Dhorda, M. *et al.* Artemisinin-resistant malaria in Africa demands urgent action.
578 *Science* **385**, 252–254 (2024).
- 579 24. Rosado, J. *et al.* *Ex vivo* susceptibility to antimalarial drugs and polymorphisms in
580 drug resistance genes of African *Plasmodium falciparum*, 2016-2023: a genotype-
581 phenotype association study. *bioRxiv* (2024) doi:10.1101/2024.07.17.24310448.
- 582 25. Hamlet, A. *et al.* The potential impact of *Anopheles stephensi* establishment on the
583 transmission of *Plasmodium falciparum* in Ethiopia and prospective control
584 measures. *BMC Med.* **20**, 135 (2022).
- 585 26. Messenger, L. A. *et al.* Insecticide resistance in *Anopheles arabiensis* from Ethiopia
586 (2012-2016): a nationwide study for insecticide resistance monitoring. *Malar. J.* **16**,
587 469 (2017).
- 588 27. Nigussie, T. Z., Zewotir, T. & Muluneh, E. K. Effects of climate variability and
589 environmental factors on the spatiotemporal distribution of malaria incidence in the
590 Amhara national regional state, Ethiopia. *Spat. Spatiotemporal Epidemiol.* **40**,
591 100475 (2022).
- 592 28. Tandoh, K. Z., Duah-Quashie, N. O., Raman, J. & Ochola-Oyier, L. I. Editorial:
593 Malaria molecular epidemiology current situation in Africa. *Front Epidemiol* **4**,
594 1400612 (2024).
- 595 29. Inzaule, S. C., Tessema, S. K., Kebede, Y., Ogwel Ouma, A. E. & Nkengasong, J.
596 N. Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
597 *Lancet Infect. Dis.* **21**, e281–e289 (2021).
- 598 30. Schaffner, S. F. *et al.* Malaria surveillance reveals parasite relatedness, signatures
599 of selection, and correlates of transmission across Senegal. *Nat. Commun.* **14**,
600 7268 (2023).
- 601 31. Fola, A. A. *et al.* Genomics reveals heterogeneous *Plasmodium falciparum*
602 transmission and selection signals in Zambia. *Commun. Med.* **4**, 67 (2024).
- 603 32. Struelens, M. J. *et al.* Real-time genomic surveillance for enhanced control of
604 infectious diseases and antimicrobial resistance. *Front. Sci. Ser.* **2**, (2024).
- 605 33. Golumbeanu, M., Edi, C. A. V., Hetzel, M. W., Koepfli, C. & Nsanzabana, C.
606 Bridging the Gap from Molecular Surveillance to Programmatic Decisions for

- 607 Malaria Control and Elimination. *Am. J. Trop. Med. Hyg.* (2023)
608 doi:10.4269/ajtmh.22-0749.
- 609 34. Bayih, A. G. *et al.* A Unique *Plasmodium falciparum* K13 Gene Mutation in
610 Northwest Ethiopia. *Am. J. Trop. Med. Hyg.* **94**, 132–135 (2016).
- 611 35. Abera, D. *et al.* Genomic analysis reveals independent evolution of *Plasmodium*
612 *falciparum* populations in Ethiopia. *Malar. J.* **20**, 129 (2021).
- 613 36. Anderson, T. J. *et al.* Microsatellite markers reveal a spectrum of population
614 structures in the malaria parasite *Plasmodium falciparum*. *Mol. Biol. Evol.* **17**,
615 1467–1482 (2000).
- 616 37. Camponovo, F., Buckee, C. O. & Taylor, A. R. Measurably recombining malaria
617 parasites. *Trends Parasitol.* **39**, 17–25 (2023).
- 618 38. Neafsey, D. E. & Volkman, S. K. Malaria Genomics in the Era of Eradication. *Cold*
619 *Spring Harb. Perspect. Med.* **7**, (2017).
- 620 39. Auburn, S. & Barry, A. E. Dissecting malaria biology and epidemiology using
621 population genetics and genomics. *Int. J. Parasitol.* **47**, 77–85 (2017).
- 622 40. Meier-Scherling, C. P. G. *et al.* Selection of artemisinin partial resistance Kelch13
623 mutations in Uganda in 2016-22 was at a rate comparable to that seen previously
624 in South-East Asia. *medRxiv* (2024) doi:10.1101/2024.02.03.24302209.
- 625 41. Juliano, J. J. *et al.* Country wide surveillance reveals prevalent artemisinin partial
626 resistance mutations with evidence for multiple origins and expansion of high level
627 sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. *medRxiv*
628 (2023) doi:10.1101/2023.11.07.23298207.
- 629 42. Conrad, M. D. *et al.* Evolution of Partial Resistance to Artemisinins in Malaria
630 Parasites in Uganda. *N. Engl. J. Med.* **389**, 722–732 (2023).
- 631 43. Stokes, B. H. *et al.* *Plasmodium falciparum* K13 mutations in Africa and Asia impact
632 artemisinin resistance and parasite fitness. *Elife* **10**, (2021).
- 633 44. Uwimana, A. *et al.* Emergence and clonal expansion of in vitro artemisinin-resistant
634 *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda. *Nat. Med.* **26**,
635 1602–1608 (2020).
- 636 45. Ikeda, M. *et al.* Artemisinin-Resistant *Plasmodium falciparum* with High Survival
637 Rates, Uganda, 2014-2016. *Emerg. Infect. Dis.* **24**, 718–726 (2018).
- 638 46. Tukwasibwe, S. *et al.* Varied Prevalence of Antimalarial Drug Resistance Markers
639 in Different Populations of Newly Arrived Refugees in Uganda. *J. Infect. Dis.* **230**,
640 497–504 (2024).
- 641 47. Talisuna, A. O. *et al.* Mitigating the threat of artemisinin resistance in Africa:
642 improvement of drug-resistance surveillance and response systems. *Lancet Infect.*
643 *Dis.* **12**, 888–896 (2012).
- 644 48. Grais, R. F. *et al.* Molecular markers of resistance to amodiaquine plus
645 sulfadoxine–pyrimethamine in an area with seasonal malaria chemoprevention in
646 south central Niger. *Malar. J.* **17**, 1–9 (2018).
- 647 49. Okell, L. C. *et al.* Emerging implications of policies on malaria treatment: genetic
648 changes in the Pfmdr-1 gene affecting susceptibility to artemether-lumefantrine and
649 artesunate-amodiaquine in Africa. *BMJ Glob Health* **3**, e000999 (2018).
- 650 50. Veiga, M. I. *et al.* Globally prevalent PfMDR1 mutations modulate *Plasmodium*
651 *falciparum* susceptibility to artemisinin-based combination therapies. *Nat. Commun.*
652 **7**, 11553 (2016).

- 653 51. Fola, A. A. *et al.* Temporal genomic analysis of *Plasmodium falciparum* reveals
654 increased prevalence of mutations associated with delayed clearance following
655 treatment with artemisinin-lumefantrine in Choma District, Southern Province,
656 Zambia. *medRxiv* (2024) doi:10.1101/2024.06.05.24308497.
- 657 52. Eklund, E. H. & Fidock, D. A. Advances in understanding the genetic basis of
658 antimalarial drug resistance. *Curr. Opin. Microbiol.* **10**, 363–370 (2007).
- 659 53. Guyant, P. *et al.* Past and new challenges for malaria control and elimination: the
660 role of operational research for innovation in designing interventions. *Malar. J.* **14**,
661 279 (2015).
- 662 54. Arya, A., Kojom Foko, L. P., Chaudhry, S., Sharma, A. & Singh, V. Artemisinin-
663 based combination therapy (ACT) and drug resistance molecular markers: A
664 systematic review of clinical studies from two malaria endemic regions – India and
665 sub-Saharan Africa. *International Journal for Parasitology: Drugs and Drug*
666 *Resistance* vol. 15 43–56 Preprint at <https://doi.org/10.1016/j.ijpddr.2020.11.006>
667 (2021).
- 668 55. Assefa, A., Fola, A. A. & Tasew, G. Emergence of *Plasmodium falciparum* strains
669 with artemisinin partial resistance in East Africa and the Horn of Africa: is there a
670 need to panic? *Malar. J.* **23**, 34 (2024).
- 671 56. Teyssier, N. B. *et al.* Optimization of whole-genome sequencing of *Plasmodium*
672 *falciparum* from low-density dried blood spot samples. *Malar. J.* **20**, 116 (2021).
- 673 57. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of
674 *Plasmodium falciparum* in the DRC. *Nat. Commun.* **11**, 2107 (2020).
- 675 58. Li, H. Aligning sequence reads, clone sequences and assembly con*gs with BWA-
676 MEM. (2014) doi:10.6084/M9.FIGSHARE.963153.V1.
- 677 59. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read
678 sequencing. *arXiv [q-bio.GN]* (2012).
- 679 60. Danecek, P. *et al.* The variant call format and VCFtools. *Bioinformatics* **27**, 2156–
680 2158 (2011).
- 681 61. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of
682 *Plasmodium falciparum* in the DRC. *Nat. Commun.* **11**, 2107 (2020).

683

684

685

686

687

688

689

690

691

692

693

694


695 **Supplementary materials**

696

697 Supplementary Figures

698

699




700

701

702 **Figure S1. MIP sequencing coverage for genome-wide SNPs.** Heatmap color shows
703 samples ($n = 855$, columns) and loci ($n = 1415$, rows) coverage retained after
704 filtering for downstream analysis.

705

706




707

708 **Figure S2. WHO validated K13 mutations prevalence at health facility level. Bar**

709 **plots show** prevalence of the indicated mutations at health facility level per region.


710 Colours indicate mutations

711




712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731

Figure S3. Prevalence of non-synonymous mutations across the *K13* gene, coloured according to amino-acid residues within beta propeller domain where validated resistance mutations are located or not.




732
733
734
735
736
737
738
739

Figure S4. Comparison of relatedness of mutant vs wildtype. **A)** Plot shows the mean IBD within K13 P441L mutant versus wildtype parasites. **B)** Plot shows the mean IBD within K13 P574L mutant versus wild type parasites. **C)** Plot shows the mean IBD within K13 A675V mutant versus wild type parasites. Color codes correspond to *kelch13* R622I mutant and wild parasites.




740
741
742
743
744
745
746
747
748

Fig S5. Prevalence of SP (A) and CRT K76T (B) mutations in Ethiopia. **A)** commutative prevalence of different SP markers. Bars indicate individual mutation and colors indicate gene. **B)** Prevalence of CRT K76T prevalence at health facility level.



749
750
751

Figure S6. Complexity of infections across sequenced samples.



752

753 **Figure S7. Population structure of *P. falciparum* populations per 622I mutation**
754 **and Health facility level across five regions in Ethiopia.** Colors indicate geographic
755 sample origins and shapes indicate mutation status. Each diamond or dot indicates
756 individual parasites. Percentage of variance explained by each PCA presented in each
757 plot.

758

759

760

761

762

763

764

765

766

767

768

769 **Supplementary tables**

770

771 **To assess and view easily all supplementary tables compiled in one excel sheet.**

772

773 **Table S1.** Details of samples sequenced per region, health facility and year of sample
774 collection.

775

776 **Table S2.** Metadata and genotype file for all successfully sequenced samples for drug
777 resistance loci. Only successfully sequenced samples were used for drug resistance
778 marker prevalence estimates. 0=Reference call (Wildtype), 1=Alternative heterozygous
779 call (Mixed mutant), 2=Alternative homozygous call (Pure mutant), -1=Missing call. Note
780 that the number of samples successfully genotyped varies per locus drug resistance
781 MIP panel.

782

783 **Table S3.** Prevalence of key mutation per health facility, n=number samples sequenced
784 at each health center and % prevalence of key mutation.

785

786 **Table S4.** List of molecular inversion probes (IBC2CORE MIPs) designed targeting
787 genome-wide geographic informative SNPs.